EP07.05. Efficacy and Safety of Osimertinib Therapy in High-Risk Stage I EGFRm NSCLC after R0 Resection(OSTAR): A Prospective, Single-Arm Study - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Dongsheng Yue
Meta Tag
Speaker Dongsheng Yue
Topic Early-Stage NSCLC: Pushing the Boundaries
adjuvant therapy
high-risk factors
stage I NSCLC
complete resection
EGFR mutation-positive
disease-free survival
overall survival
health-related quality of life
Clinical Trials in Progress
Powered By